Pfizer wins FDA approval for Talzenna-Xtandi in earlier prostate cancer
Talzenna Xtandi FDA approval moves Pfizer's prostate cancer combination into earlier-stage treatment, backed by a 52% risk-reduction trial result.
Markets
Delayed · 00:11 UK
Topic
Every Financial News story tagged PFE, newest first.
1–2 of 2
Talzenna Xtandi FDA approval moves Pfizer's prostate cancer combination into earlier-stage treatment, backed by a 52% risk-reduction trial result.
Pfizer's tilrekimig Phase 2 atopic dermatitis trial hit its primary endpoint, with the drug now advancing into Phase 3 studies in two indications.